Bisphosphonate-associated osteonecrosis of the jaw

Menopause International

Volumn 13, Issue 2, 2007, Pages 56-59

  Basu, Neil ^a   Reid, David m ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

BISPHOSPHONATES; BONE; BONE CANCER; OSTEONECROSIS; OSTEOPOROSIS

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PHOSPHORUS; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIBIOTIC THERAPY; APOPTOSIS; BONE INFECTION; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; DENTAL HEALTH; DRUG HALF LIFE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; FACE DEFORMITY; HEAD AND NECK CANCER; HUMAN; HYPERBARIC OXYGEN; JAW OSTEONECROSIS; METABOLIC BONE DISEASE; NEOPLASM; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PREVENTIVE DENTISTRY; RADIATION INJURY; REVIEW; TOOTH DISEASE; TREATMENT INDICATION; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; FEMALE; JAW DISEASE; UNITED KINGDOM; WOMEN'S HEALTH;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GREAT BRITAIN; HUMANS; JAW DISEASES; OSTEONECROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; WOMEN'S HEALTH;

EID: 36049049024     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507780796361     Document Type: Review

References (27)

1. Landis B, Richter M, Dojcinovic I, Hugentobler M. Osteonecrosis of the jaw after treatment with bisphosphonates. BMJ 2006;333: 982–3.
2. Flint SR, Sharkey S, Galvin S. Warning: bisphosphonates and osteochemonecrosis of the jaws. J Ir Dent Assoc 2006;52:79–83.
3. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010–18.
4. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189–99.
5. Woo SB, Hellstein JW, Kalmar JR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753–61.
6. Odvina CV, Zerwekh JE, Rao S, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90: 1294–1301.
7. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 2005;56:365–78.
8. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20: 3719–36.
9. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238–9.
10. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182: 413–15.
11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–17.
12. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508–14.
13. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35:801–3.
14. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006;21:1503–5.
15. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682–9.
16. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620–3.
17. Reuther T, Schuster T, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients – a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003;32:289–95.
18. Morrish RB Jr, Chan E, Silverman S Jr, et al. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer 1981; 47:1980–3.
19. Thorn JJ, Hansen HS, Specht L, Bastholt L. Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation. J Oral Maxillofac Surg 2000;58:1088–93.
20. Morton ME, Simpson W. The management of osteoradionecrosis of the jaws. Br J Oral Maxillofac Surg 1986;24:332–41.
21. Waldron H. Lecture Notes in Occupational Medicine. 4th edn. London: Blackwell Scientific, 1990.
22. Anonymous. Necrosis of the lower jaw in makers of lucifer matches. Am J Dent Science 1867;1:96–97.
23. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006; 137:1144–50.
24. American College of Rheumatology. Bisphosphonate-associated osteonecrosis of the jaw. See www.rheumatology.org/publications/hotline/0606onj.asp, last accessed March 2007.
25. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433–41.
26. Pickett FA, American Academy of Oral Medicine. Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg 2006;80:10.
27. Schwartz HC. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982;4:251–3.